Navigation Links
Harbour Antibodies BV Signs Research and Licence Agreement With Lilly
Date:6/24/2011

ROTTERDAM, The Netherlands, June 24, 2011 /PRNewswire-iReach/ -- Harbour Antibodies BV, an Erasmus MC spin-off company,  announced today the completion of a non-exclusive research and licence agreement with Eli Lilly and Company ("Lilly"), a global pharmaceutical company, to generate and develop human therapeutic antibodies comprising immunoglobulin heavy and light chains(H2L2) using one of Harbour's transgenic mouse antibody discovery platforms.

Under the terms of the agreement Harbour will receive an upfront payment, success-based fees, and potential downstream product milestones and royalties. Specific financial terms were not disclosed.

"We are delighted to partner with Lilly," said Professor Frank Grosveld, The Head of Cell Biology and Genetics at ErasmusMC, and the Chief Scientific Officer of Harbour Antibodies BV. "Transgenic mice utilise the natural immune response and have proved over the last decade to be a very reliable route to discover potential human antibody based medicines. Recent industry acquisitions leave scope for new transgenic mouse platforms to meet the continuing clinical need for therapeutic antibody discovery. The Harbour H2L2 transgenic mouse platform will meet this need".

About Harbour Antibodies BV:

Harbour Antibodies BV was founded in December 2006 as a virtual company to commercialise transgenic mouse antibody platforms being developed at the Department of Cell Biology ErasmusMC.  In addition to the derivation of human H2L2 antibodies, transgenic mouse platforms have been developed for the derivation of novel second generation human and camelised human heavy chain only antibodies (HCAbs),  soluble human VH domains and  VH domain antibody complexes for use both as research tools and to meet unmet clinical need. The proprietary transgenic mouse platforms are protected by filed and granted patent applications in the major and the expanding healthcare markets. Harbour plans to partner broadly across the Pharmaceutical industry, and provide access to the transgenic mouse antibody platforms under MTA to academic partners where target antigens provided the basis of novel strategies for clinical intervention.

Further information on the Harbour technology platforms and management team can be found on the company's website at www.harbourantibodies.com or contact :

Roger Craig at r.craig@harbourantibodies.com     or

Bob Kamen at  r.kamen@harbourantibodies.com

For further information, please contact Sylvia Marmelstein, Press Officer Erasmus MC Tel:  +31 (0)10 703 5285 or E-mail s.marmelstein@erasmusmc.nl

About Erasmus MC and the Department of Cell Biology and Genetics:

The Erasmus Medical Center is situated in the centre of Rotterdam, the Netherlands and comprises the Academic Hospital and the Faculty of Medicine of the Erasmus University. It employs 13.000 people and is the largest medical centre in the country.

The Department of Cell Biology comprises a number of research groups that are primarily focussed on stem cell biology and developmental biology of mammals related to human disease. The regulation of transcription in vivo is a primary research focus. The Department boasts excellent genomics and proteomics facilities and has extensive experience in working with transgenic animals.

Media Contact: Roger Craig Harbour Antibodies, +31 (0)10 703 5285, r.craig@harbourantibodies.com


'/>"/>
SOURCE Harbour Antibodies BV
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Proceedings of the National Academy of Sciences (PNAS) Publishes Roche Manuscript on Production of Bispecific IgG Antibodies
2. Morphotek Receives Grant to Support Development of Therapeutic Antibodies against Biowarfare Agents
3. OriGene Releases 1500 TrueMAB™ Monoclonal Antibodies
4. UNC-led team tests commonly used antibodies
5. Reportlinker Adds Triple Analysis: Lymphoma, Cancer Vaccines and Antibodies
6. Diagenode Releases Two New Epigenetic Monoclonal 5-hmC Antibodies for Quantifying Global Hydroxymethylation
7. Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation
8. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
9. Michael J. Fox Foundation Offers High-Quality LRRK2 Antibodies for PD Therapeutic Development
10. OriGene Technologies Raises $16 Million to Build the Largest Collection of Next Generation Monoclonal Antibodies (TrueMAB(TM)) to Cover the Majority of Human Proteome
11. Generation of Fully Human Monoclonal Antibodies Neutralizing Influenza Virus - Use of SPYMEG as a novel human lymphocyte fusion partner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , ... May 26, 2016 , ... ... company, today announced several positive developments that position the Company for the future. ... of the transaction, Craig F. Kinghorn has been appointed Chairman of the Board, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of the Fitzmaurice ... surgery and surgery of the hand by the National Board of Physicians and ... above and beyond in his pursuit of providing the most comprehensive, effective treatment ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... U.S. Food and Drug Administration (FDA) has granted the company’s orphan drug designation ... company’s second orphan drug designation granted by the FDA. , Spinocerebellar ataxia ...
(Date:5/23/2016)... , ... May 23, 2016 , ... The need for blood donations in South Texas ... by the South Texas Blood & Tissue Center, blood donations are on the decline. In ... and they are down 21 percent in South Texas in the last four years alone. ...
Breaking Biology Technology:
(Date:3/15/2016)... New York , March 15, 2016 ... new market report published by Transparency Market Research "Digital Door ... Trends and Forecast 2015 - 2023," the global digital door ... US$ 731.9 Mn in 2014 and is forecast to grow ... 2023. Growth of micro, small and medium enterprises (MSMEs) across ...
(Date:3/14/2016)... -- NXTD ) ("NXT-ID" or the "Company"), a ... airing of a new series of commercials on Time Warner ... st .  The commercials will air on Bloomberg TV, Fox ... Street show. --> NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ...
(Date:3/11/2016)... HANOVER, Germany , March 11, 2016 ... - Cross reference: Picture is available at AP Images ( ... scanner from DERMALOG will be used to produce the new refugee ... of other biometric innovations, at CeBIT in Hanover ... LF10 scanner from DERMALOG will be used to produce the new ...
Breaking Biology News(10 mins):